FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Home Diagnostics, Inc. (Nasdaq:HDIX - News), a leading manufacturer and marketer of diabetes testing supplies, announced today the Board of Directors has retained the executive search firm DavenportMajor to recruit a successor to J. Richard Damron, Jr., President and Chief Executive Officer, who will be departing the company following a transition to the new President and CEO. Mr. Damron will remain in his present role until a transition is completed, which is expected to be in the first half of 2009.
“We appreciate the dedication that Dick has provided to Home Diagnostics over his eight year tenure at the Company,” said George H. Holley, Chairman of the Board of Home Diagnostics. “Dick’s leadership in growing Home Diagnostics and the transition to public ownership has been invaluable in positioning the Company for future growth and success. We wish him the best in his future endeavors and appreciate his commitment to work with the company through the transition to a successor.”
“Since becoming President, Chief Executive Officer and a director of Home Diagnostics in February 2001, we have achieved a number of major milestones,” said J. Richard Damron, Jr., President and Chief Executive Officer of Home Diagnostics. “With these accomplishments, I believe the Company is poised for its next stage of growth and the time is appropriate for me to move on to my next professional challenge.”
About Home Diagnostics, Inc.
Based in Fort Lauderdale, Florida, Home Diagnostics, Inc. (NASDAQ: HDIX - News) is a leading developer, manufacturer and marketer of diabetes management solutions. Home Diagnostics, Inc. offers a portfolio of high-quality blood glucose monitoring systems that spans the spectrum of features and benefits to help every person with diabetes better monitor and manage their disease. The Home Diagnostics, Inc. product line includes TRUE2go™, TRUEresult™, TRUEtest™, TRUEtrack™, Sidekick®, TRUEread™ and Prestige IQ® blood glucose monitoring systems. The products are available in more than 45,000 pharmacies throughout the U.S. Home Diagnostics is the exclusive co-brand supplier of blood glucose monitoring supplies for leading pharmacies including CVS, Rite Aid and Walgreens as well as national distributors such as AmerisourceBergen, Cardinal Health and McKesson. For more information please visit www.homediagnostics.com.
Forward-Looking Statements
The above statements include forward-looking statements and are subject to risks and uncertainties. Forward-looking statements give the Company’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. The statements can be identified by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.
All statements other than statements of historical facts included in this release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements.
These forward-looking statements are largely based on our expectations and beliefs concerning future events, which reflect estimates and assumptions made by the Company’s management. These estimates and assumptions reflect the Company’s best judgment based on currently known market conditions and other factors relating to the Company’s operations and business environment, all of which are difficult to predict and many of which are beyond its control.
Although the Company believes its estimates and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond the Company’s control. In addition, management’s assumptions about future events may prove to be inaccurate. Management cautions all readers that the forward-looking statements contained in this release are not guarantees of future performance, and the Company cannot assure any reader that those statements will be realized or the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied in the forward-looking statements due to the factors listed in the “Risk factors” and “Management’s discussion and analysis of financial condition and results of operations” sections contained in its filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release. The Company does not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by law. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.
TRUE2go, TRUEresult, TRUEtest, TRUEtrack, Sidekick, TRUEread and Prestige IQ are trademarks of Home Diagnostics, Inc. All other trademarks are property of their respective owners.
[HDIX-F]
Contact:
Home Diagnostics, Inc., Fort Lauderdale Sabrina Rios, Corporate Communications Manager, 954-332-2141 srios@hdidiabetes.com or The Ruth Group Nick Laudico (investors), 646-536-7030 nlaudico@theruthgroup.com or Schwartz Communications Courtney Smith (media), 781-684-0770 homediagnostics@schwartz-pr.com
Source: Home Diagnostics, Inc.
